What do Analysts Say about Cancer Genetics, Inc.(NASDAQ:CGIX): Marathon Patent Group, Inc.(NASDAQ:MARA)

0
3

Cancer Genetics, Inc. (CGIX) will report its next earnings on Aug 27 BMO. The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.16/share. The difference between the expected and actual EPS was $0.02/share, which represents an Earnings surprise of 12.5%.

Many analysts are providing their Estimated Earnings analysis for Cancer Genetics, Inc. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

In case of Revenue Estimates, 1 analysts have provided their consensus Average Revenue Estimates for Cancer Genetics, Inc. as 10.77 Million. According to these analysts, the Low Revenue Estimate for Cancer Genetics, Inc. is 10.77 Million and the High Revenue Estimate is 10.77 Million. The company had Year Ago Sales of 7.67 Million.

Some buy side analysts are also providing their Analysis on Cancer Genetics, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Cancer Genetics, Inc. might touch $3 high while the Average Price Target and Low price Target is $3 and $3 respectively.

Cancer Genetics, Inc. closed its last trading session at $0.09 with the gain of 5.09%. The Market Capitalization of the company stands at 5.9 Million. The Company has 52-week high of $1.30 and 52-week low of $0.09. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -9.42% where SMA50 and SMA200 are -29.48% and -55.63% respectively. The Company Touched its 52-Week High on 09/21/18 and 52-Week Low on 08/28/19.

The Relative Volume of the company is 0.99 and Average Volume (3 months) is 2.29 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -54.8%. The Return on Equity (ROE) value stands at -288.5%. While it’s Return on Investment (ROI) value is -122.8%.

While looking at the Stock’s Performance, Cancer Genetics, Inc. currently shows a Weekly Performance of -4.71%, where Monthly Performance is -25.49%, Quarterly performance is -47.23%, 6 Months performance is -60.88% and yearly performance percentage is -89.84%. Year to Date performance value (YTD perf) value is -59.05%. The Stock currently has a Weekly Volatility of 8.19% and Monthly Volatility of 11.50%.

Marathon Patent Group, Inc. (MARA) will report its next earnings on Aug 12 AMC. The company reported the earnings of $-1.6/Share in the last quarter where the estimated EPS by analysts was $-2.24/share. The difference between the expected and actual EPS was $0.64/share, which represents an Earnings surprise of 28.6%.

Many analysts are providing their Estimated Earnings analysis for Marathon Patent Group, Inc. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

In case of Revenue Estimates, 1 analysts have provided their consensus Average Revenue Estimates for Marathon Patent Group, Inc. as 163 Million. According to these analysts, the Low Revenue Estimate for Marathon Patent Group, Inc. is 5 Million and the High Revenue Estimate is 5 Million. The company had Year Ago Sales of 43 Million.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Marathon Patent Group, Inc. might touch $64 high while the Average Price Target and Low price Target is $64 and $64 respectively.

Marathon Patent Group, Inc. closed its last trading session at $1.83 with the loss of -1.09%. The Market Capitalization of the company stands at 11.48 Million. The Company has 52-week high of $3.97 and 52-week low of $1.32. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.03% where SMA50 and SMA200 are -14.74% and -20.9% respectively. The Company Touched its 52-Week High on 04/10/19 and 52-Week Low on 01/31/19.

The Relative Volume of the company is 0.21 and Average Volume (3 months) is 211.65 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -128.5%. The Return on Equity (ROE) value stands at -222.8%. While it’s Return on Investment (ROI) value is -238.3%.

While looking at the Stock’s Performance, Marathon Patent Group, Inc. currently shows a Weekly Performance of 8.38%, where Monthly Performance is -13.4%, Quarterly performance is -14.22%, 6 Months performance is -26.72% and yearly performance percentage is -49.72%. Year to Date performance value (YTD perf) value is 24.93%. The Stock currently has a Weekly Volatility of 8.05% and Monthly Volatility of 8.55%.

SHARE